Haemonetics (NYSE:HAE) and Trident Brands (OTCMKTS:TDNT) Critical Contrast

Trident Brands (OTCMKTS:TDNT) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.

Profitability

This table compares Trident Brands and Haemonetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trident Brands	N/A	N/A	N/A
Haemonetics	12.67%	27.22%	9.52%

Volatility & Risk

Trident Brands has a beta of -4.09, indicating that its share price is 509% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Valuation & Earnings

This table compares Trident Brands and Haemonetics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trident Brands	N/A	N/A	N/A	N/A	N/A
Haemonetics	$1.36 billion	2.75	$167.68 million	$3.42	23.39

Haemonetics has higher revenue and earnings than Trident Brands.

Insider & Institutional Ownership

99.7% of Haemonetics shares are owned by institutional investors. 33.9% of Trident Brands shares are owned by company insiders. Comparatively, 1.8% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Trident Brands and Haemonetics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trident Brands	0	0	0	0	0.00
Haemonetics	1	3	7	2	2.77

Haemonetics has a consensus price target of $84.10, suggesting a potential upside of 5.11%. Given Haemonetics’ stronger consensus rating and higher possible upside, analysts plainly believe Haemonetics is more favorable than Trident Brands.

Summary

Haemonetics beats Trident Brands on 10 of the 11 factors compared between the two stocks.

About Trident Brands

Trident Brands Incorporated, together with its subsidiaries, focuses on developing branded consumer products and ingredients in the nutritional supplement, life sciences, and food and beverage categories in the United States and Canada. The company develops, markets, and sells a portfolio of DHA supplements under the Brain Armor brand. It also holds various banking facilities; and licenses associated with the manufacturing, importation, and sale of natural health and nutrition products. The company was formerly known as Sandfield Ventures Corp. and changed its name to Trident Brands Incorporated in July 2013. Trident Brands Incorporated was incorporated in 2007 and is based in Boca Raton, Florida.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.